117 related articles for article (PubMed ID: 11858907)
1. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
Jones RN; Biedenbach DJ; Anderegg TR
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):119-22. PubMed ID: 11858907
[TBL] [Abstract][Full Text] [Related]
2. Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
Anderegg TR; Jones RN
Int J Antimicrob Agents; 2004 Jan; 23(1):6-10. PubMed ID: 14732307
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
Anderegg TR; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 2002 Aug; 46(8):2662-4. PubMed ID: 12121951
[TBL] [Abstract][Full Text] [Related]
4. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
Ednie LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):101-5. PubMed ID: 12096013
[TBL] [Abstract][Full Text] [Related]
5. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
J Antimicrob Chemother; 2002 Aug; 50(2):271-6. PubMed ID: 12161411
[TBL] [Abstract][Full Text] [Related]
7. AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro.
Wookey A; Turner PJ; Greenhalgh JM; Eastwood M; Clarke J; Sefton C
Clin Microbiol Infect; 2004 Mar; 10(3):247-54. PubMed ID: 15008947
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci.
Anderegg TR; Biedenbach DJ; Jones RN
J Antimicrob Chemother; 2002 Jun; 49(6):1019-21. PubMed ID: 12039896
[TBL] [Abstract][Full Text] [Related]
9. Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.
Anderegg TR; Jones RN;
Diagn Microbiol Infect Dis; 2003 Jan; 45(1):73-6. PubMed ID: 12573554
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
[TBL] [Abstract][Full Text] [Related]
13. Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.
Peric M; Lin G; Clark CL; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2002 Jul; 50(1):95-100. PubMed ID: 12096012
[TBL] [Abstract][Full Text] [Related]
14. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program.
Jones RN; Stilwell MG; Hogan PA; Sheehan DJ
Antimicrob Agents Chemother; 2007 Apr; 51(4):1491-3. PubMed ID: 17210770
[TBL] [Abstract][Full Text] [Related]
15. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
[TBL] [Abstract][Full Text] [Related]
16. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
Jones RN; Anderegg TR; Deshpande LM
Diagn Microbiol Infect Dis; 2002 May; 43(1):87-90. PubMed ID: 12052634
[TBL] [Abstract][Full Text] [Related]
17. A multicenter evaluation of linezolid antimicrobial activity in North America.
Ballow CH; Jones RN; Biedenbach DJ;
Diagn Microbiol Infect Dis; 2002 May; 43(1):75-83. PubMed ID: 12052632
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the new oxazolidinone AZD2563 against Enterococci.
Eliopoulos GM; Wennersten CB; Moellering RC
Antimicrob Agents Chemother; 2002 Oct; 46(10):3273-5. PubMed ID: 12234858
[TBL] [Abstract][Full Text] [Related]
19. Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.
Jones RN; Anderegg TR; Biedenbach DJ
Clin Microbiol Infect; 2003 Jun; 9(6):543-6. PubMed ID: 12848732
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2004 Jun; 48(6):2149-52. PubMed ID: 15155214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
